These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Prognostic value of high sensitivity C-reaction protein in non-insulin dependent diabetes mellitus patients with non-alcoholic fatty liver disease. Bi Y; Min M; Shen W; Deng P; Du Q; Dong M; Liu Y Int J Clin Exp Pathol; 2015; 8(7):8494-9. PubMed ID: 26339423 [TBL] [Abstract][Full Text] [Related]
45. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). Tasneem AA; Luck NH; Majid Z Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775 [TBL] [Abstract][Full Text] [Related]
46. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986 [TBL] [Abstract][Full Text] [Related]
47. Diagnosis and management of fatty liver. Tan PO; Mustaffa N; Tan SS; Lee YY J R Coll Physicians Edinb; 2020 Sep; 50(3):256-261. PubMed ID: 32936098 [TBL] [Abstract][Full Text] [Related]
48. Nonalcoholic fatty liver disease as a multi-systemic disease. Fotbolcu H; Zorlu E World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660 [TBL] [Abstract][Full Text] [Related]
51. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333 [TBL] [Abstract][Full Text] [Related]
52. Non-Alcoholic Fatty Liver Disease, an Overview. Nd AM Integr Med (Encinitas); 2019 Apr; 18(2):42-49. PubMed ID: 31341444 [TBL] [Abstract][Full Text] [Related]
53. [Metabolic syndrome and the liver (NAFLD/NASH)]. Hůlek P; Dresslerová I Vnitr Lek; 2009; 55(7-8):646-9. PubMed ID: 19731869 [TBL] [Abstract][Full Text] [Related]
54. A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence. Temple JL; Cordero P; Li J; Nguyen V; Oben JA Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27314342 [TBL] [Abstract][Full Text] [Related]
55. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471 [TBL] [Abstract][Full Text] [Related]
56. Steatosis and NASH in type 2 diabetes. Hu M; Phan F; Bourron O; Ferré P; Foufelle F Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281 [TBL] [Abstract][Full Text] [Related]
57. Liver fibrosis markers of nonalcoholic steatohepatitis. Enomoto H; Bando Y; Nakamura H; Nishiguchi S; Koga M World J Gastroenterol; 2015 Jun; 21(24):7427-35. PubMed ID: 26139988 [TBL] [Abstract][Full Text] [Related]
58. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Perumpail RB; Wong RJ; Ahmed A; Harrison SA Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831 [TBL] [Abstract][Full Text] [Related]
59. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity. Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682 [TBL] [Abstract][Full Text] [Related]
60. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]